Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-02-08 Sale |
2023-02-10 5:00 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
12,000 | $54.45 | $653,400 | 1,172,250 (Direct) |
View |
| 2023-02-03 Sale |
2023-02-06 5:35 pm |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
5,000 | $55.85 | $279,250 | 365,432 (Direct) |
View |
| 2023-02-01 Sale |
2023-02-02 4:15 pm |
Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director |
500 | $52.61 | $26,305 | 404,831 (Indirect Direct) |
View |
| 2023-01-30 Sale |
2023-01-31 4:51 pm |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
883 | $52.76 | $46,587 | 46,468 (Direct) |
View |
| 2023-01-30 Sale |
2023-01-31 4:47 pm |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
883 | $52.76 | $46,587 | 36,459 (Direct) |
View |
| 2023-01-23 Sale |
2023-01-25 4:17 pm |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
2,955 | $51.58 | $152,419 | 37,709 (Direct) |
View |
| 2023-01-23 Sale |
2023-01-25 4:14 pm |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
4,479 | $51.58 | $231,027 | 47,718 (Direct) |
View |
| 2023-01-17 Sale |
2023-01-19 4:55 pm |
Apellis Pharmaceuticals Inc. | APLS | Machiels Alec Director |
1,250 | $52.42 | $65,525 | 791,870 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-10 Tax Withholding |
2023-02-14 4:42 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
3,958 | $51.21 | 1,566,696 (Direct) |
View |
| 2023-02-10 Tax Withholding |
2023-02-14 4:28 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
1,134 | $51.21 | 1,005,622 (Direct) |
View |
| 2023-02-10 Tax Withholding |
2023-02-14 4:24 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
670 | $51.21 | 46,502 (Direct) |
View |
| 2023-02-08 Exercise |
2023-02-10 5:00 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
18,500 | $2.67 | 1,172,250 (Direct) |
View |
| 2023-02-08 Exercise |
2023-02-10 5:00 pm |
N/A 2023-12-05 |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
18,500 | $0 | 1,172,250 (Direct) |
View |
| 2023-02-03 Exercise |
2023-02-06 5:35 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
5,000 | $15.09 | 365,432 (Direct) |
View |
| 2023-02-03 Exercise |
2023-02-06 5:35 pm |
N/A 2028-11-15 |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
5,000 | $0 | 365,432 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 5:19 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
551 | $52.77 | 176,439 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 5:07 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
551 | $52.77 | 67,932 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 5:05 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
551 | $52.77 | 124,211 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 5:03 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer |
542 | $52.77 | 61,150 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 5:02 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
551 | $52.77 | 54,442 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 5:01 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
367 | $52.77 | 37,342 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 4:59 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
2,879 | $52.77 | 1,570,654 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 4:58 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
367 | $52.77 | 47,351 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 4:47 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
832 | $52.77 | 1,000,256 (Direct) |
View |
| 2023-01-27 Tax Withholding |
2023-01-30 4:45 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
367 | $52.77 | 47,172 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:33 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
2,034 | $52.05 | 176,990 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:32 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
1,912 | $52.05 | 68,483 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:23 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
2,379 | $52.05 | 124,762 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:22 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer |
2,015 | $52.05 | 61,692 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:21 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
2,034 | $52.05 | 54,993 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:20 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
1,411 | $52.05 | 40,664 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:17 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
9,453 | $52.05 | 1,573,533 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:15 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
2,033 | $52.05 | 52,197 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:14 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
2,326 | $52.05 | 1,001,088 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 5:12 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
1,149 | $52.05 | 47,539 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 4:58 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer |
919 | $52.05 | 27,153 (Direct) |
View |
| 2023-01-20 Tax Withholding |
2023-01-24 4:57 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Brown Victoria L. Program Team Lead |
1,412 | $52.05 | 23,556 (Direct) |
View |
| 2023-01-17 Exercise |
2023-01-19 4:55 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Machiels Alec Director |
1,250 | $2.67 | 791,870 (Direct) |
View |
| 2023-01-17 Exercise |
2023-01-19 4:55 pm |
N/A 2023-12-04 |
Apellis Pharmaceuticals Inc. | APLS | Machiels Alec Director |
1,250 | $0 | 791,870 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 8:00 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
27,488 | $0 | 174,074 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 8:00 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
43,183 | $52.66 | 174,074 (Direct) |
View |
| 2022-04-25 Other |
2023-01-17 8:00 pm |
N/A 2031-01-27 |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
26,250 | $0 | 174,074 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:46 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
53,455 | $0 | 216,732 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:46 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
37,708 | $52.66 | 216,732 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:44 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
27,488 | $0 | 113,578 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:44 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
43,183 | $52.66 | 113,578 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:42 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer |
22,580 | $0 | 99,179 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:42 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer |
35,472 | $52.66 | 99,179 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:41 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
22,580 | $0 | 94,374 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:41 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
35,472 | $52.66 | 94,374 (Direct) |
View |
| 2022-04-25 Other |
2023-01-17 7:41 pm |
N/A 2031-01-27 |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
13,125 | $0 | 94,374 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:39 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
19,634 | $0 | 74,170 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:39 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
30,845 | $52.66 | 74,170 (Direct) |
View |
| 2022-04-25 Other |
2023-01-17 7:39 pm |
N/A 2031-01-27 |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
8,750 | $0 | 74,170 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:37 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
83,447 | $0 | 1,714,079 (Direct) |
View |
| 2023-01-12 Option Award |
2023-01-17 7:37 pm |
N/A 2033-01-11 |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
131,093 | $52.66 | 1,714,079 (Direct) |
View |
| 2022-04-25 Other |
2023-01-17 7:37 pm |
N/A 2031-01-27 |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
75,000 | $0 | 1,714,079 (Direct) |
View |